FDA Grants Orphan Drug Exclusivity for YUVIWEL, Now Commercially Available in US
Summary
Ascendis Pharma announced that its drug YUVIWEL received Orphan Drug Exclusivity from the FDA and is now commercially available in the United States, securing market protection until 2033.
Key Events
-
Orphan Drug Exclusivity Granted
YUVIWEL (navepegritide) received Orphan Drug Exclusivity (ODE) from the U.S. FDA, providing market protection through February 27, 2033.
-
Commercial Availability in U.S.
YUVIWEL is now commercially available in the United States, marking a key step for revenue generation.
-
First and Only Once-Weekly Treatment
YUVIWEL is the first and only FDA-approved once-weekly treatment for increasing linear growth in children with achondroplasia, offering continuous systemic exposure to CNP.
Analysis
This 6-K filing officially announces a significant regulatory and commercial milestone for Ascendis Pharma. The grant of Orphan Drug Exclusivity (ODE) by the FDA for YUVIWEL (navepegritide) provides market protection until February 27, 2033, securing a competitive advantage for the company's new treatment for achondroplasia. The immediate commercial availability in the U.S. means the company can begin generating revenue from this product. While the news was previously reported by Dow Jones Newswires on the same day, this filing serves as the official company disclosure to the SEC, confirming the details of this important development.
At the time of this filing, ASND was trading at $228.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13.9B. The 52-week trading range was $124.06 to $248.60. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.